Results of Annual General Meeting

RNS Number : 2095B
Advanced Medical Solutions Grp PLC
08 June 2021

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Results of Annual General Meeting

 

Winsford, UK, 8 June 2021 Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that at the Company’s Annual General Meeting held today at 11 am at Guildhall Room, 85 Gresham Street, London, EC2V 7NQ, all resolutions were duly passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 30 April 2021.

 

The poll results were as follows.

 

Resolution

 

Title

For (see note 2)

Against (see note 2)

No. of shares

%

No. of shares

%

1

Receive Annual Report and Accounts

120,604,593

99.99

330,181

0.01

2

Approve the Remuneration Report

120,394,128

99.73

5,741,835

0.27

3

Re-appoint Deloitte LLP as auditors

114,997,737

95.24

12,404,976

4.76

4

Re-elect Peter Allen

108,344,248

89.73

7,340,112

10.27

5

Re-elect Penny Freer

108,168,473

93.65

107,035

6.35

6

Elect Grahame Cook

120,642,189

99.91

596,840

0.09

7

Re-elect Chris Meredith

120,152,803

99.51

335,974

0.49

8

Re-elect Eddie Johnson

120,413,250

99.72

500

0.28

9

Declare final dividend

120,757,509

99.99

411,061

0.01

10

Authorise allotment of shares

115,674,585

99.65

12,886,611

0.35

11

Disapply pre-emption rights*

107,809,178

89.32

897,163

10.68

12

Authorise purchase of own shares*

94,716,196

99.06

330,181

0.94

*  Special Resolution

Notes:

1.  Votes “For” and “Against” are expressed as a percentage of votes received.

2.  A “Vote withheld” is not a vote in law and is not counted in the calculation of the votes “For” or “Against” a resolution.

3.  Total number of shares in issue at close of business on 4 June = 215,650,692 shares. 56% of the voting capital was instructed.

 

Ends –

 

 

 

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Mary-Jane Elliott / Matthew Neal / Matthew Cole

AMS@consilium-comms.com

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Daniel Adams / Gary Clarence / Patrick Robb

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.

 

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSFFDAEFSEEM